# Complement System Dysregulation in the Immunopathogenesis of Long COVID: Systematic Evidence Synthesis

**Authors:** Kin Israel Notarte, Jesus Alfonso Catahay, Jacqueline Veronica Velasco, Abbygail Therese Ver, Jungwook Lee, John G. Rizk, Giuseppe Lippi, César Fernández-de-las-Peñas

PMC · DOI: 10.3390/biomedicines14020439 · Biomedicines · 2026-02-15

## TL;DR

This study reviews evidence that the immune complement system may be dysregulated in people with long COVID, but findings are inconsistent and more research is needed.

## Contribution

This is the first systematic review to evaluate the role of long-lasting complement activation in long COVID.

## Key findings

- Elevated markers of classical, alternative, and terminal complement pathways were found in some long COVID patients.
- Markers of the lectin pathway showed no significant differences between long COVID patients and controls.
- Heterogeneous results and methodological differences highlight the need for further research.

## Abstract

Background/Objective: Long COVID is an important cause of disability following SARS-CoV-2 infection; yet, its underlying mechanisms are not completely understood. One proposed mechanism is the long-lasting dysregulation of the immune complement system. This systematic review is the first to summarize the current evidence and evaluate the potential role of long-lasting complement activation in people with long COVID. Methods: A systematic electronic search on PubMed, MEDLINE, CINAHL, and Embase was conducted up to 15 October 2025, to identify studies investigating complement activation in people with the post-COVID-19 condition. The Newcastle–Ottawa Scale was used to evaluate the risk of bias and methodological quality. Results: Among the 247 studies initially identified, eleven met the inclusion criteria, comprising 1435 individuals (age: 48.5 years, 70% females) with long COVID and 1124 controls (age: 43.6 years, 60% females). All studies were of a high quality, with scores ranging from 7 to 8 stars (mean: 7.6 ± 0.5). The activation of the classical complement pathway was investigated in nine studies, whereas the lectin, alternative, and terminal complement pathways were each assessed in three studies. Multiple studies investigated several complement pathways. The results were heterogeneous since several markers of complement activation spanning the classical (C2, C4a, C4b, and C1s-C1INH), alternative (Ba, iC3b, and Factor D), and terminal (C5bC6, C5a, C9, and TCC) pathways were elevated, whereas other markers were not significantly different (C3, C4, and C4d) between patients with/without long COVID. In addition, markers spanning the lectin complement pathway (MBL, and MASP1-C1INH) were not significantly different between individuals with and without long COVID. Conclusions: The current evidence suggests potential long-lasting complement system dysregulation in individuals with long COVID, although the clinical significance remains controversial, due to heterogenous findings. Specific post-COVID symptom clusters, such as fatigue, dyspnea, or brain fog, have been linked to a distinct pattern of complement dysregulation. Substantial methodological heterogeneity, including differences in follow-up periods, complement markers, assessment methods, and control groups, along with the small number of available studies, underscores the need for further research to clarify the mechanisms linking complement dysregulation to long COVID.

## Linked entities

- **Proteins:** C2 (complement C2), C4A (complement C4A (Chido/Rodgers blood group)), C4B (complement C4B (Chido/Rodgers blood group)), ba (bare), C5 (complement C5), C9 (complement C9), SFXN1 (sideroflexin 1), C3 (complement C3), C4A (complement C4A (Chido/Rodgers blood group)), MBL2 (mannose binding lectin 2)

## Full-text entities

- **Genes:** PTX3 (pentraxin 3) [NCBI Gene 5806] {aka TNFAIP5, TSG-14}, C3 (complement C3) [NCBI Gene 718] {aka AHUS5, ARMD9, ASP, C3a, C3b, CPAMD1}, SFXN1 (sideroflexin 1) [NCBI Gene 94081] {aka SLC56A1, TCC}, C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, C1QC (complement C1q C chain) [NCBI Gene 714] {aka C1Q-C, C1QD3, C1QG}, MBL2 (mannose binding lectin 2) [NCBI Gene 4153] {aka COLEC1, HSMBPC, MBL, MBL2D, MBP, MBP-C}, C4B (complement C4B (Chido/Rodgers blood group)) [NCBI Gene 721] {aka C4B1, C4B12, C4B3, C4B5, C4BD, C4F}, MASP1 (MBL associated serine protease 1) [NCBI Gene 5648] {aka 3MC1, CRARF, CRARF1, MAP-1, MAP1, MASP}, C1S (complement C1s) [NCBI Gene 716] {aka EDSPD2}, C4A (complement C4A (Chido/Rodgers blood group)) [NCBI Gene 720] {aka C4, C4A2, C4A3, C4A4, C4A6, C4AD}, SERPING1 (serpin family G member 1) [NCBI Gene 710] {aka C1IN, C1INH, C1NH, HAE1, HAE2}, LPCAT3 (lysophosphatidylcholine acyltransferase 3) [NCBI Gene 10162] {aka C3F, LPCAT, LPLAT 5, LPLAT12, LPSAT, MBOAT5}, C5AR1 (complement C5a receptor 1) [NCBI Gene 728] {aka C5A, C5AR, C5R1, CD88}, CFP (complement factor properdin) [NCBI Gene 5199] {aka BFD, PFC, PFD, PROPERDIN}, MBL3P (mannose-binding lectin family member 3, pseudogene) [NCBI Gene 50639] {aka COLEC2, MBL}, COLEC12 (collectin subfamily member 12) [NCBI Gene 81035] {aka CLP1, NSR2, SCARA4, SRCL}
- **Diseases:** diarrhea (MESH:D003967), chest pain (MESH:D002637), gastrointestinal or cognitive post-COVID symptoms (MESH:D019954), Fatigue (MESH:D005221), hair loss (MESH:D000505), autoimmune (MESH:D001327), Obesity (MESH:D009765), vomiting (MESH:D014839), damage (MESH:D020263), systemic lupus erythematosus (MESH:D008180), dysgeusia (MESH:D004408), sleep disturbance (MESH:D012893), injury to (MESH:D014947), gastrointestinal problems (MESH:D012817), inflammation (MESH:D007249), headache (MESH:D006261), abdominal pain (MESH:D015746), dyspnea (MESH:D004417), insomnia (MESH:D007319), chronic (MESH:D002908), Post-COVID (MESH:D000094024), cognitive dysfunction (MESH:D003072), Brain fog (MESH:D005222), tissue injury (MESH:D017695), complement dysregulation (OMIM:614878), complement (MESH:D007153), cardiorespiratory symptoms (MESH:D012816), thrombosis (MESH:D013927), dizziness (MESH:D004244), vascular injury (MESH:D057772), immune or endothelial dysfunction (MESH:D007154), COVID (MESH:D000086382), coagulation (MESH:D001778), infected (MESH:D007239)
- **Chemicals:** carbohydrate (MESH:D002241)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938500/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938500/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938500/full.md

---
Source: https://tomesphere.com/paper/PMC12938500